162 related articles for article (PubMed ID: 36943367)
1. Design of phase II oncology trials evaluating combinations of experimental agents.
Sharon E; Foster JC
J Natl Cancer Inst; 2023 Jun; 115(6):613-618. PubMed ID: 36943367
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
Bayar MA; Ivanova A; Le Teuff G
Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
[TBL] [Abstract][Full Text] [Related]
4. [Randomized Phase II Trial Designs in Oncology].
Yoshimura K
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Tan AC; Bagley SJ; Wen PY; Lim M; Platten M; Colman H; Ashley DM; Wick W; Chang SM; Galanis E; Mansouri A; Khagi S; Mehta MP; Heimberger AB; Puduvalli VK; Reardon DA; Sahebjam S; Simes J; Antonia SJ; Berry D; Khasraw M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215688
[TBL] [Abstract][Full Text] [Related]
6. Designs of drug-combination phase I trials in oncology: a systematic review of the literature.
Riviere MK; Le Tourneau C; Paoletti X; Dubois F; Zohar S
Ann Oncol; 2015 Apr; 26(4):669-674. PubMed ID: 25403591
[TBL] [Abstract][Full Text] [Related]
7. Practical designs for Phase I combination studies in oncology.
Wages NA; Ivanova A; Marchenko O
J Biopharm Stat; 2016; 26(1):150-66. PubMed ID: 26379085
[TBL] [Abstract][Full Text] [Related]
8. Tailoring early-phase clinical trial design to address multiple research objectives.
Wages NA; Slingluff CL; Bullock TN; Petroni GR
Cancer Immunol Immunother; 2020 Jan; 69(1):95-102. PubMed ID: 31807879
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II trials: time for a new era in clinical trial design.
Mandrekar SJ; Sargent DJ
J Thorac Oncol; 2010 Jul; 5(7):932-4. PubMed ID: 20581575
[TBL] [Abstract][Full Text] [Related]
10. A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.
Barnett H; George M; Skanji D; Saint-Hilary G; Jaki T; Mozgunov P
Stat Methods Med Res; 2024 Feb; 33(2):203-226. PubMed ID: 38263903
[TBL] [Abstract][Full Text] [Related]
11. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
[TBL] [Abstract][Full Text] [Related]
12. Early phase clinical trials in oncology: Realising the potential of seamless designs.
Jaki T; Burdon A; Chen X; Mozgunov P; Zheng H; Baird R
Eur J Cancer; 2023 Aug; 189():112916. PubMed ID: 37301716
[TBL] [Abstract][Full Text] [Related]
13. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors.
Martorana F; Colombo I; Treglia G; Gillessen S; Stathis A
Cancer Treat Rev; 2021 Dec; 101():102300. PubMed ID: 34688105
[TBL] [Abstract][Full Text] [Related]
15. Looking ahead in early-phase trial design to improve the drug development process: examples in oncology.
Vanderbeek AM; Redd RA; Ventz S; Trippa L
BMC Med Res Methodol; 2023 Jun; 23(1):151. PubMed ID: 37386450
[TBL] [Abstract][Full Text] [Related]
16. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Araujo D; Greystoke A; Bates S; Bayle A; Calvo E; Castelo-Branco L; de Bono J; Drilon A; Garralda E; Ivy P; Kholmanskikh O; Melero I; Pentheroudakis G; Petrie J; Plummer R; Ponce S; Postel-Vinay S; Siu L; Spreafico A; Stathis A; Steeghs N; Yap C; Yap TA; Ratain M; Seymour L
Ann Oncol; 2023 Jan; 34(1):48-60. PubMed ID: 36182023
[TBL] [Abstract][Full Text] [Related]
17. Oncology Combination Dose-Finding Study Design for Targeted and Immuno-Oncology Therapies.
Zhou L; Reddy MB; Mittapalli RK; Yang J; Yin D
Clin Pharmacol Ther; 2024 Jan; 115(1):29-35. PubMed ID: 37881828
[TBL] [Abstract][Full Text] [Related]
18. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
20. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
